Advertisement
Drug Pipeline
Subscribe to Drug Pipeline

The Lead

FDA Approves Actavis', Medicines360's Long-Term Contraception

March 2, 2015 10:06 am | News | Comments

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, announced the approval of Liletta (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration (FDA) for use by women to prevent pregnancy for up to three years. Read more...

First Treatment Approved in Canada for Adults With ADPKD

March 2, 2015 9:52 am | News | Comments

Otsuka Pharmaceutical Co., Ltd. and its affiliate Otsuka Canada Pharmaceutical Inc. announce...

Sanofi Gets FDA Approval for New Insulin Drug

February 26, 2015 12:06 pm | by Stephanie Guzowski, Editor | News | Comments

Sanofi announced late Wednesday that it received approval from the U.S. Food and Drug...

Amgen: Positive Results for CKD Treatment

February 26, 2015 11:05 am | News | Comments

Amgen announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet ...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Ampio: Results of Injections STRUT Study

February 25, 2015 10:11 am | by Ampio Pharmaceuticals | News | Comments

Ampio Pharmaceuticals, Inc. announced results of the double-blind, multiple injection, vehicle controlled STRUT study (N=40) at 20 weeks. Read more..

BioDelivery Sciences to Receive $10M from Endo Pharmaceuticals

February 23, 2015 10:56 am | News | Comments

BioDelivery Sciences International, Inc. and Endo Pharmaceuticals Inc., a subsidiary of Endo International plc announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Belbuca. Read more..

Asthma Drug Improves Lung Function: Phase 3 Data

February 23, 2015 10:13 am | News | Comments

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase 3 trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Houston, Texas. Read more..

Advertisement

Oral Med Shows Promise in Hormone-Resistant Breast Cancer

February 23, 2015 10:03 am | News | Comments

​Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments. Read more...

Lilly Provides Update on Evacetrapib Phase 3 Trial

February 20, 2015 12:25 pm | News | Comments

Eli Lilly and Company has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months. Read more....

FDA Expands Indications for Revlimid

February 18, 2015 10:40 am | by Associated Press | News | Comments

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the existing indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). Read more..

Lupin, Celon: Development, Licensing for Generic Advair Diskus

February 17, 2015 10:02 am | News | Comments

​Pharma Major Lupin Limited (Lupin) and Celon Pharma S.A. (Celon) announced that they have entered into a definitive agreement under which the companies will jointly develop a fluticasone/salmeterol dry powder inhaler (DPI) product which is a generic version of GlaxoSmithKline's Advair Diskus. Read more...

Drug Abuse in Iran Rising Despite Executions, Police Raids

February 13, 2015 10:34 am | by Ali Akbar Dareini - Associated Press | News | Comments

Officials say methamphetamine production and abuse of hard drugs are skyrocketing in the country despite potentially lethal criminal penalties for users if they are caught. Read more...            

Advertisement

Closing the Knowledge Gap on Cancer Drug Toxicity

February 12, 2015 3:59 pm | by David Jackson, Ph.D., Chief Innovation Officer, MolecularHealth | Articles | Comments

There is a dangerous knowledge gap in the use of cancer medications that needs to be closed, immediately. Read more...                                                          

Science is Afire With Plans to Help Smokers Quit

February 12, 2015 12:25 pm | by Cynthia Fox, Science Editor | Articles | Comments

All types of scientists are at work, on all kinds of quit-smoking aids, from an anti-smoking vaccine to a biomarker test. Read more...                                         

Eisai's Thyroid Cancer Drug: Phase 3 Trial

February 12, 2015 11:38 am | News | Comments

Results from the pivotal Phase 3 SELECT (Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid) trial evaluating the use of investigational agent lenvatinib in the treatment of progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC) were published online in the New England Journal of Medicine (NEJM). Read more..

Cumberland Pharmaceuticals: Pipeline Expansion with AERD Drug

February 12, 2015 11:10 am | News | Comments

Cumberland Pharmaceuticals Inc. announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin exacerbated respiratory disease (AERD). Read more..

CDK4/6 Inhibitor: Promising Results for Treating Breast Cancer

February 9, 2015 1:06 pm | by Drug Discovery & Development staff | Articles | Comments

The words “exciting,” “breakthrough,” and “standard-of-care-changing” are being used with regard to cyclin-dependent kinase (CDK) 4 and 6 inhibitors and metastatic breast cancer. Read more...                                       

Advertisement

Achillion Shares Soar Following Hepatitis C Drug Update

February 9, 2015 11:57 am | by Associated Press | News | Comments

Shares of Achillion Pharmaceuticals Inc. jumped Monday morning after the drug developer said a small group of patients who took its experimental hepatitis C treatment combination remained free of the liver-destroying virus three months after they stopped taking doses. Read more...

Theravance Biopharma, Mylan to Develop COPD Compound

February 2, 2015 10:14 am | by Theravance Biopharma | News | Comments

Theravance Biopharma, Inc. and Mylan Inc. announced that the two companies will partner on the development and, subject to FDA approval, commercialization of TD-4208, a novel investigational once-daily nebulized long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD) and other respiratory diseases. Read more...

AbbVie: Top-line Results from Phase 3 Hepatitis C Treatment

February 2, 2015 10:04 am | by AbbVie | News | Comments

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. Read more...

New Approach to Delay Alzheimer's Onset to Be Tested

January 29, 2015 10:22 am | by Alzheimer's Drug Discovery Foundation | News | Comments

The Alzheimer's Drug Discovery Foundation (ADDF) announced a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. Read more...                       

Regeneron, Sanofi: FDA Accepts BLA for Hyperchoestrolemia Drug

January 26, 2015 10:20 am | by Sanofi | News | Comments

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for PraluentTM (alirocumab). Under the Prescription Drug User Fee Act (PDUFA), the goal for a priority review is six months, for a target action date of July 24, 2015. Read more...

FDA Approves Prestalia's Hypertension Treatment

January 26, 2015 10:00 am | by Prestalia | News | Comments

Symplmed Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Prestalia (perindopril arginine and amlodipine) tablets, licensed from Servier (Suresnes, France), for the treatment of hypertension.           

Meningococcal Vaccine Gets FDA Approval

January 26, 2015 9:44 am | by FDA | News | Comments

The U.S. Food and Drug Administration today approved Bexsero, a vaccine to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Read more..                       

FDA Clears Roche's MRSA/SA Test

January 26, 2015 9:32 am | by Roche | News | Comments

Roche announced that the US Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas MRSA/SA Test for the early, simultaneous detection of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus (SA) directly from nasal specimens. Read more...

FDA Approves Novartis' Psoriasis Drug

January 22, 2015 11:44 am | by Novartis | News | Comments

Novartis announced the US Food and Drug Administration (FDA) has approved Cosentyx™ (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.                           

Pharmalink: Open IND Application for IgA Nephropathy

January 21, 2015 9:59 am | by Pharmalink | News | Comments

Pharmalink AB, a specialty pharma company focused on orphan and niche products, announces that its IND for Nefecon is now open with the US Food & Drug Administration (FDA). Read more...                                  

Boehringer Ingelheim: Inhalation Spray Available in U.S.

January 21, 2015 9:53 am | by Boehringer Ingelheim | News | Comments

Boehringer Ingelheim Pharmaceuticals, Inc. announced that Spiriva Respimat(tiotropium bromide) Inhalation Spray is now available by prescription through retail pharmacies across the United States. Read more...                                                         

Bausch + Lomb Introduces New Optical Software

January 21, 2015 9:47 am | by Valeant Pharmaceuticals | News | Comments

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an advanced Swept Source OCT (Optical Coherence Tomography) imaging system and updated software for its VICTUS Femtosecond Laser Platform that will provide surgeons with a new, redesigned interface. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading